Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Heart and Blood Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Lymphoma, Large B-Cell, Diffuse

Leukemia, Lymphoid

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoma, Non-Hodgkin

Leukemia, B-Cell

Chronic Disease

Disease Attributes

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Chronic Graft Versus Host Disease

Lymphosarcoma

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Follicular Lymphoma

Patients who received previous treatment with JCAR017

Patients who received previous treatment with JCARH125

No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.

JCAR017

No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.

JCARH125

Jacob Garcia, MD

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

Genomic DNA prepared from peripheral blood mononuclear cells

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial

Juno Therapeutics, a Subsidiary of Celgene

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Patients who received previous treatment with JCAR015

No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.

JCAR015

Bristol-Myers Squibb

This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.

Long-Term Follow-up Study for Patients Previously Treated With JCAR015

Long-Term Follow-up Protocol for Subjects Treated With JCAR015

Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT

Total T-Cell Dose: 1 x 10\^4 cells/kg

Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT

Total T-Cell Dose: 1 x 10\^5 cells/kg

Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT

Total T-Cell Dose: 2 x 10\^5 cells/kg

Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT

Total T-Cell Dose: 4 x 10\^5 cells/kg

Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg

CAR T-Cell Infusion

Miguel-Angel Perales, MD

The purposed of this study is to determine whether an infusion with specialized 'modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker will reduce the risk of relapse after transplant.

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

A Phase I Trial Evaluating the Safety of Consolidative Infusions of CD19-Specific Chimeric Antigen Receptor (CAR) T Cells Following T-cell Depleted Allogeneic Transplantation for High Risk B-cell Malignancies

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

To determine maximum tolerated dose (MTD) of intravenously administered allogeneic, donor-derived 19-28z CAR T cells administered following TCD allo-HSCT for patients with high-risk CD19+ malignancies

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product	NCT03436771	Non Hodgkin Lym... Multiple Myelom... Chronic Lymphoc... Diffuse Large B... Mantle Cell Lym... Follicular Lymp...	JCAR017 JCARH125	-	Juno Therapeutics, a Subsidiary of Celgene
Long-Term Follow-up Study for Patients Previously Treated With JCAR015	NCT02813252	Acute Lymphobla...	JCAR015	18 Years -	Juno Therapeutics, a Subsidiary of Celgene
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies	NCT04556266	Leukemia Lymphoma Lymphoma, B-Cel...	CAR T-Cell Infu...	18 Years - 60 Years	Memorial Sloan Kettering Cancer Center
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product	NCT03436771	Non Hodgkin Lym... Multiple Myelom... Chronic Lymphoc... Diffuse Large B... Mantle Cell Lym... Follicular Lymp...	JCAR017 JCARH125	-	Juno Therapeutics, a Subsidiary of Celgene

Spots Global Cancer Trial Database for chimeric antigen receptor (car) t cells